61062-56-4Relevant articles and documents
N-(1-CYANO-PYRROLIDIN-3-YL)-5-(3-(TRIFLUOROMETHYL)PHENYL)OXAZOLE-2-CARBOXAMIDE DERIVATIVES AND THE CORRESPONDING OXADIAZOLE DERIVATIVES AS USP30 INHIBITORS FOR THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION
-
, (2021/12/08)
The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibros
New insights into the bacterial RNA polymerase inhibitor CBR703 as a starting point for optimization as an anti-infective agent
Zhu, Weixing,Haupenthal, J?rgm,Groh, Matthias,Fountain, Michelle,Hartmann, Rolf W.
supporting information, p. 4242 - 4245 (2014/07/08)
CBR703 was reported to inhibit bacterial RNA polymerase (RNAP) and biofilm formation, considering it to be a good candidate for further optimization. While synthesized derivatives of CBR703 did not result in more-active RNAP inhibitors, we observed promising antibacterial activities. These again correlated with a significant cytotoxicity toward mammalian cells. Furthermore, we suspect the promising effects on biofilm formation to be artifacts. Consequently, this class of compounds can be considered unattractive as antibacterial agents. Copyright
Rapid development and scale-up of a 1 H -4-substituted imidazole intermediate enabled by chemistry in continuous plug flow reactors
May, Scott A.,Johnson, Martin D.,Braden, Timothy M.,Calvin, Joel R.,Haeberle, Brian D.,Jines, Amy R.,Miller, Richard D.,Plocharczyk, Edward F.,Rener, Gregory A.,Richey, Rachel N.,Schmid, Christopher R.,Vaid, Radhe K.,Yu, Hannah
, p. 982 - 1002 (2012/08/27)
The development of reactions in a continuous fashion in plug flow tube reactors (PFR) offers unique advantages to the drug development and scale-up process and can also enable chemistry that would be difficult to perform via batch processing. Herein, we r
P70 S6 KINASE INHIBITORS
-
Page/Page column 16, (2009/01/20)
The present invention provides p70 S6 kinase inhibitors of the formula: pharmaceutical formulations comprising them, and methods for their use.